About Lonapegsomatropin Dosing

This guide provides supplementary clinical information for the Lonapegsomatropin Dose Calculator. It covers the dosing principles, administration guidelines, and safety context for lonapegsomatropin-tcgd (Skytrofa®) when used for pediatric growth hormone deficiency (GHD) at the standard 0.24 mg/kg/week regimen.

Outputs Explained

The calculator provides the following key outputs for clinical verification:

• Total Weekly Dose (mg): The precise dose of lonapegsomatropin required for one week, calculated to two decimal places for accuracy.
• Weight in Kilograms (kg): Displays the patient’s weight in kg used for the calculation, automatically converted from pounds (lbs) if necessary.
• Dosing Formula: Shows the exact calculation performed (e.g., 25.00 kg × 0.24 mg/kg = 6.00 mg/week) for complete transparency.
• Clinical Note: A warning message appears if the patient’s weight is outside the approved range (≥11.5 kg), prompting the clinician to verify the weight and use clinical judgment.

How to Use the Calculator

To determine the weekly dose, follow these simple steps:

1. Enter Patient Weight: Input the patient’s current weight into the provided field.
2. Select Weight Unit: Choose between kilograms (kg) and pounds (lbs). The tool performs conversions automatically.
3. Review Results: The recommended weekly dose and the underlying calculation are displayed instantly for review.

Dosing Overview

Lonapegsomatropin (Skytrofa®) is a long-acting growth hormone approved for pediatric patients aged one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone.

• Recommended Dosage: The standard dose is 0.24 mg/kg of actual body weight, administered once weekly.
• Administration: The dose is administered via subcutaneous injection. Injection sites should be rotated to reduce the risk of lipoatrophy.
• Dose Titration: Doses should be individualized based on clinical response and serum insulin-like growth factor-1 (IGF-1) concentrations. Refer to the full prescribing information for monitoring and adjustment guidelines.

Switching from Daily Somatropin

Patients being treated with daily somatropin injections can be switched to weekly lonapegsomatropin. The recommended starting dose is 0.24 mg/kg/week. The first dose of lonapegsomatropin can be administered the day after the patient’s last daily somatropin injection.

Missed Dose Protocol

If a weekly dose of lonapegsomatropin is missed:

• If it is within 3 days of the scheduled dose, administer it as soon as possible.
• If more than 3 days have passed, skip the missed dose entirely.
• Resume the regular weekly dosing schedule with the next planned dose. Do not administer a double dose to compensate for a missed one.

Safety Alerts

Clinicians must review the full safety profile before prescribing. Key contraindications for lonapegsomatropin include:

• Acute critical illness following surgery, trauma, or respiratory failure.
• Active malignancy.
• Known hypersensitivity to lonapegsomatropin or any of its excipients.
• Closed epiphyses in pediatric patients seeking growth promotion.

Monitor patients for potential adverse events, including intracranial hypertension, pancreatitis, glucose intolerance, and fluid retention. The most common adverse reactions include viral infection, pyrexia, cough, nausea, vomiting, diarrhea, abdominal pain, and arthralgia.

Frequently Asked Questions (FAQ)

1. What is lonapegsomatropin (Skytrofa®)?

Skytrofa® is a long-acting prodrug of somatropin administered once-weekly for the treatment of pediatric GHD. It is designed to release active growth hormone over the course of a week.

2. Is this calculator a substitute for professional medical advice?

No. This tool is for informational purposes only and does not replace clinical judgment. Always consult the full Prescribing Information before making treatment decisions.

3. Why is the minimum patient weight 11.5 kg?

The efficacy and safety of lonapegsomatropin have been established in clinical trials for pediatric patients weighing at least 11.5 kg (approximately 25.4 lbs).

4. How does the calculator handle weights entered in pounds (lbs)?

It automatically converts the weight from pounds to kilograms using the standard conversion factor (1 lb = 0.453592 kg) before applying the 0.24 mg/kg dosing formula.

5. Should the calculated dose be rounded?

The Skytrofa® auto-injector allows for precise dose dialing. Doses should be administered as calculated without rounding, as per the device instructions. Select the appropriate prefilled cartridge strength to deliver the prescribed dose.

6. Can this calculator be used for adults or other indications?

No. This calculator is specifically designed for pediatric patients with GHD, based on the approved 0.24 mg/kg/week regimen. It should not be used for other patient populations or indications.

7. How is Skytrofa® supplied?

Skytrofa® is supplied in single-patient-use, prefilled cartridges containing various concentrations of lonapegsomatropin to be used with the Skytrofa® auto-injector.

8. Where should Skytrofa® be injected?

It should be injected subcutaneously into the abdomen, buttocks, or thigh. Rotate injection sites with each dose to avoid tissue damage.

References

1. Skytrofa® (lonapegsomatropin-tcgd) Prescribing Information. Ascendis Pharma, Inc. Accessed via U.S. Food and Drug Administration. View PDF
2. U.S. Food and Drug Administration. Drugs@FDA: Skytrofa. accessdata.fda.gov
3. Skytrofa® HCP Website. Ascendis Pharma. www.skytrofa-hcp.com
4. Thornton PS, Miller BS, Bentsen D, et al. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial. J Clin Endocrinol Metab. 2021;106(11):3184-3195. doi:10.1210/clinem/dgab529